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Abstract
Pancreatic neoplasms are morphologically and genetically heterogeneous and include wide variety 
of neoplasms ranging from benign to malignant with an extremely poor clinical outcome. Our 
understanding of these pancreatic neoplasms has improved significantly with recent advances in 
cancer sequencing. Awareness of molecular pathogenesis brings in new opportunities for early 
detection, improved prognostication, and personalized gene-specific therapies. Here we review the 
pathological classification of pancreatic neoplasms from their molecular and genetic perspective.
All of the major tumor types that arise in the pancreas have been sequenced, and a new 
classification that incorporates molecular findings together with pathological findings is now 
possible (Table 1). This classification has significant implications for our understanding of why 
tumors aggregate in some families, for the development of early detection tests, and for the 
development of personalized therapies for patients with established cancers. Here we describe this 
new classification using the framework of the standard histological classification.
Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignant neoplasm of 
pancreas. Unfortunately it is one of the most lethal of all of the solid malignancies. The 
American Cancer Society (Cancer Facts & Figures 2014; www.cancer.org) has estimated 
that 46,420 Americans will be diagnosed with pancreatic cancer in 2014 and that 39,590 will 
die of the disease.1
Grossly, most ductal adenocarcinomas form poorly demarcated and firm white-yellow 
masses. The adjacent non-neoplastic pancreas is typically atrophic and fibrotic, and the 
pancreatic ducts may be dilated from the obstructive effects of the carcinoma. 
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Microscopically, these neoplasms vary from well-differentiated duct forming carcinomas, 
which may be so well-differentiated as to mimic non-neoplastic glands, to poorly-
differentiated carcinomas with glandular differentiation demonstrable only 
onimmunolabeling.2 Ductal adenocarcinomas typically elicit an intense stromal reaction, 
and this reaction has been postulated to serve as a barrier to chemotherapy.3, 4
The pancreatic parenchyma adjacent to invasive ductal adenocarcinomas often contains 
epithelial proliferations in smaller pancreatic ducts, called pancreatic intraepithelial 
neoplasia (PanIN) lesions. PanINs are one of the precursors to invasive ductal 
adenocarcinoma.5 PanINs contain many of the genetic alterations that are present in invasive 
ductal adenocarcinomas.6–9 PanINs are graded histologically from PanIN-1 to PanIN-3 
based on architectural complexity and cytological atypia, with PanIN-3 lesions having the 
most atypia.10
Molecular Genetics of pancreatic ductal adenocarcinoma
The genomes or exomes of a large number of ductal adenocarcinomas have been sequenced, 
significantly increasing our understanding of the molecular drivers of pancreatic 
cancer.11, 12 Although the genetic changes identified are complex, the key to understanding 
of pancreatic tumorigenesis lies in recognition and appreciation that these mutations target a 
core set of pathways and processes. The core genes and pathways targeted in ductal 
adenocarcinomas include KRAS, p16/CDKN2A, TP53, the TGF-β signaling pathway as well 
as other less commonly targeted pathways. The KRAS, p16/CDKN2A, TP53 and SMAD4 
genes are each mutated in more than 50% of ductal adenocarcinomas. (Table 1)
KRAS—The oncogene KRAS (short arm of chromosome 12p) is the most commonly 
mutated gene in ductal adenocarcinomas, with alterations present in >90% of the cancers. 
These mutations occur early in tumorigenesis, as KRAS gene mutations are present in greater 
than 90% of PanIN-1 lesions.7
The KRAS oncogene encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) protein 
which belongs to the GTPase family of proteins. Somatic activating mutations in KRAS most 
frequently target codon 12 of the gene, resulting in substitution of glycine with aspartic acid, 
valine, arginine or serine in the protein-product of the gene.11 These amino acid changes 
constitutively activate the KRAS protein by decreasing its intrinsic GTPase activity and 
rendering the mutant protein insensitive to GTPase-activating proteins. Constitutive KRAS 
activation leads to activation of a number of complex downstream pathways such as the 
RAF-MEK-ERK pathway that governs proliferation, cell survival, differentiation and gene 
expression. As will be discussed in greater detail later in this review, pancreatic ductal 
adenocarcinomas that do not harbor a KRAS gene mutation, are often microsatellite unstable 
and have a unique medullary histologic phenotype with poor differentiation and pushing 
borders.13
It has recently been suggested that oncogenic KRAS alters the regulation of metabolism in 
neoplastic cells.14–16 Regulated metabolic pathways include glutamine metabolism 
supporting the maintenance of redox state in the tumor cells,17 and activation of 
detoxification of reactive oxygen species18 by inducing the expression of NRF2. Other key 
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cellular functions regulated by KRAS include adaptation to higher energy needs of tumor 
cells. Activated oncogenic KRAS may also promote the direct acquisition of albumin from 
extracellular space by macropinocytosis allowing the neoplastic cells to utilize albumin for 
Krebs cycle intermediates.19 KRAS has also been implicated in inducing autophagy, which 
is a regulated catabolic cell organelle and macromolecule utilization pathway, required for 
maintainence and progression of PDAC.20
Several downstream effector pathways are affected by mutant KRAS. Of these, the mitogen 
activated protein kinase (MAPK) and PI3K pathways have been the most extensively 
studied. The MAPK pathway is a kinase cascade involving activation of RAF kinase by 
KRAS and eventual activation of MEK1/2. MEK kinases further activate ERK1/2 via 
phosphorylation. This signaling is active in PanIN lesions as well as invasive ductal 
adenocarcinomas.21,22 These downstream effector pathways are clinically important because 
they may be therapeutically targetable. The hope is to exploit the vulnerability of 
downstream effector pathways, in particular RAF – MEK – ERK, to develop specifically 
targeted therapies using kinase inhibitors.
It has also been suggested that oncogenic KRAS, in addition to transforming growth factor β 
(TGF-β) signaling, affects the fibroinflammatory stromal response characteristic of PDAC. 
The reversibility of inducible KRAS in iKras mouse has been exploited to demonstrate the 
regression of cellular stroma to an inactive scar like histology, loss of proliferation and loss 
of smooth muscle actin expression in the tumor associated stroma following inactivation of 
KRASG12D.21–23 Mutant KRAS mediated upregulation of GLI1/IL6 axis via Sonic Hedgehog 
augments the symbiotic paracrine signaling with the active fibroblast rich stroma.24–26 
Suppression of host immunosurveillance had also been postulated as one of the mechanism 
driven by mutant KRAS pathway.27 The precursor PanIN lesions are shown to adapt to the 
host immunologic defenses at an early stage by establishing an immune suppressive 
environment consisting predominantly of regulatory T cells and myeloid derived suppressor 
cells and lack of tumor infiltrating effector or cytotoxic T cells.28, 29
Activating point mutations in KRAS therefore play an early, important and multifaceted role 
in the development of ductal adenocarcinoma of the pancreas. The biology of exactly how 
mutant KRAS promotes tumorigenesis is complex, as the protein product of the KRAS gene 
impacts a large number of different pathways.
p16/CDKN2A—A number of tumor suppressor genes are targeted in ductal 
adenocarcinomas. These include p16/CDKN2A, TP53 and SMAD4/DPC4.11,30–35
The p16/CDKN2A gene (chromosome 9p) is the most commonly inactivated tumor 
suppressor gene, targeted in 95% of ductal adenocarcinomas. The protein product of the 
p16/CDKN2A gene, p16INK4A, normally functions to inhibit the G1 phase of the cell cycle 
by inhibiting the cyclin D dependent kinases (CDK4 and CDK6) and therefore the 
phosphorylation of retinoblastoma protein.33 Loss of p16INK4A occurs early in pancreatic 
tumorigenesis and plays a significant role in disease progression.7,34 The CDKN2A locus 
also encodes p14ARF in humans (p19ARF in mouse). The protein p14ARF stabilizes the 
p53tumor suppressor protein through neutralization of MDM2. Loss of p14ARF can be seen 
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in up to 40% of ductal adenocarcinomas due to homozygous deletion of CDKN2A.35 The 
resulting MDM2 activation promotes degradation of p53 through ubiquitinization in an early 
stage of pancreatic carcinogenesis causing faster progression of Pan-IN lesions to an 
invasive tumor. Thus, the almost universal inactivation of p16/CDKN2A results in the loss of 
an important cell cycle control mechanism in pancreatic cancer.
SMAD4—Tumor suppressor gene SMAD4 (DPC4, MADH4) is inactivated in ~55% of 
ductal adenocarcinomas.11,36 SMAD4 (chromosome 18q21.2) codes for the protein Smad4, 
which is involved in transforming growth factor β (TGF-β) signaling. In ductal 
adenocarcinomas, the gene can be inactivated through homozygous deletions or deletion of 
one allele coupled with an intragenic mutation in the second allele.36,37 The result is loss of 
TGF-β induced tumor suppression. Immunolabeling for the SMAD4 gene product, Smad4, 
has been shown to be sensitive and specific marker for SMAD4 gene status and may be used 
to support the diagnosis of a metastasis as from a pancreatic primary.38 This diagnostic 
utility is valid only when there is complete absence of protein on immunohistochemical 
labeling (Fig 1A), which is seen in 55% of invasive pancreatic cancers. In addition, SMAD4 
gene status of primary tumor has been shown to correlate with a poorer outcome39 and with 
widespread metastases in autopsy studies.40 SMAD4 loss has also been associated with 
worse survival in surgically resected patients.41
TP53—TP53 (chromosome 17p) is inactivated in ~75% of ductal adenocarcinomas, almost 
always by missense mutations coupled with loss of the remaining allele.11,30 The protein 
encoded by TP53 (p53) plays an important role in DNA repair mechanisms, cell growth 
arrest and activation of apoptosis following the cellular injury. TP53 is targeted late in 
PanIN progression, usually not until PanIN-3.8 Of interest, Kanda et al have recently 
reported the detection of mutant TP53 alleles in pancreatic juice samples collected 
endoscopically from patients with lesions with high-grade dysplasia in their pancreata, 
highlighting the potential of these mutations as a strategy for early detection.8
Telomeres
In comparison to normal chromosomes, telomeres are shortened during pancreatic 
tumorigenesis. Telomeres are located at the ends of chromosomes and are composed of 
repetitive nucleotide sequences and associated proteins. Telomeres prevent the free ends of 
chromosomes from sticking to each other. Telomere shortening is an early event in 
tumorigenesis in the pancreas as telomere shortening has been observed in PanIN lesions.42 
Similarly telomere shortening is present in acinar to ductal metaplasia lesions associated 
with PanIN but not in isolated acinar-to-ductal metaplasia.43 When telomeres are shortened, 
the ends of chromosomes may inappropriately stick together, causing the formation of 
anaphase bridges and chromosome instability.
Variants of pancreatic ductal adenocarcinoma
A number of morphological variants of ductal adenocarcinoma have been characterized at 
the molecular level, and these histologically and molecularly defined variants have distinct 
clinical features. For example, colloid carcinoma is characterized by the production of 
copious amounts of extracellular mucin, and these distinctive neoplasms almost always arise 
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in association with an intestinal-type intraductal papillary mucinous cystic neoplasm 
(IPMN).44 The majority of intestinal-type intraductal papillary mucinous neoplasms (as well 
as their associated carcinomas) harbors GNAS gene mutations, and, of interest, colloid 
carcinomas are often lower-stage and therefore associated with a better prognosis than 
ductal adenocarcinomas.45–47
The medullary variant of pancreatic cancer is a poorly differentiated variant of pancreatic 
cancer. The medullary variant has a higher prevalence of microsatellite instability related to 
defects in mismatch repair and BRAF mutations, but these neoplasms lack somatic KRAS 
mutations.13,48 Although the medullary variant is associated with pancreatic cancers that 
have defects in mismatch repair, not allmedullary pancreatic cancers have microsatellite 
instability.13,49 The intense host immune response associated with microsatellite unstable 
cancers suggests that they are more recognizable by the host immune system, and the 
instability may damage genes coding for proteins needed for the neoplastic cells to function. 
Thus, the medullary variant of pancreatic cancer is a great example in which an 
understanding of the genetics (microsatellite instability) helps us understand why a poorly 
differentiated neoplasm is associated with a better prognosis.
Undifferentiated carcinomas of the pancreas (pancreatic cancers with non-cohesive 
phenotype) are characterized by loss of expression of e-cadherin protein expression, 
sometimes through promoter hypermethylation.50 Some of these pancreatic cancers with 
loss of e-cadherin expression have signet ring features. These carcinomas are important to 
recognize because they are associated with a worse prognosis. Interestingly, focal loss of e-
cadherin expression is seen in many pancreatic ductal adenocarcinomas and is associated 
with a poorer outcome.51
Other variants of pancreatic cancer, such as the adenosquamous carcinoma, undifferentiated 
carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells are all important 
to recognize because they are associated with poor prognosis.2
Cystic Neoplasms of the Pancreas
Pancreatic cysts are not uncommon, and more pancreatic cysts are being detected as imaging 
techniques improve. As many as 20% of autopsied patients have a cystic lesion in their 
pancreas.52 Similarly, the prevalence of pancreatic cysts among patients undergoing 
pancreatic MRI for suspected disease is high. (~ 19.6%)53 MRI/MRCP is a more sensitive 
test for detecting pancreatic cysts than CT54 but pancreatic cysts are still commonly detected 
among patients having CT scans performed for non-pancreatic indications (detection rate of 
2.6% in asymptomatic patients).55 Among healthy individuals who have undergone a 
screening MRI, the prevalence of pancreatic cysts increases with age, with a prevalence of 
>10% among those aged 70 or more.56 These cysts are important because some, such as the 
intraductalpapillary mucinous neoplasm, are curable precursors to invasive ductal 
adenocarcinoma, while others, such as serous cystadenomas, are virtually always benign. 
Recent genetic sequencing has shown that each of the major types of cystic neoplasms of the 
pancreas has its own mutational profile.
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Intraductal Papillary Mucinous Neoplasm
Intraductal papillary mucinous neoplasms (IPMNs) account for at least 25–30% of all 
neoplastic cysts. By definition, intraductal papillary mucinous neoplasms are mucin-
producing epithelial neoplasms that involve the duct system and are equal to or larger than 
1cm in size. These neoplasms are noninvasive and can harbor varying degrees of dysplasia. 
IPMNs may involve the main or smaller branch pancreatic ducts. Most arise in the head of 
the pancreas; however, they may also arise in the tail of the gland, and some even involve 
the entire pancreas. Intraductal papillary mucinous neoplasms may be multicenteric, and 
therefore the presence of one lesion should heighten the clinical suspicion for additional 
lesions and mandate careful follow-up.
Macroscopically, IPMNs are characterized by dilatation of the main or branch pancreatic 
ducts.2 Papillary fronds of neoplastic epithelium and tenacious luminal mucin are often 
present. Microscopically, by definition, the neoplastic epithelium involves the larger 
pancreatic ducts. The neoplastic epithelium can be papillary or flat, and can show one of 
four directions of differentiation: intestinal, gastric, pancreatobiliary or oncocytic 
differentiation.5 The intestinal type includes goblet cells and intestinal-type mucin, the 
gastric type is composed of foveloar and pyloric epithelium resembling gastric glands, the 
oncocytic has abundant eosinophilic granular cytoplasm, and the pancreatobiliary type is 
more cuboidal cells with minimal mucin. Although IPMNs are typically classified into a 
histological subtype, more than one epithelial subtypes can be present within the same 
IPMN.5
The degree of dysplasia in intraductal papillary mucinous neoplasms is graded from low to 
intermediate to high based on cytological as well as architectural microscopic features.2 
Among patients with IPMNs who go to pancreatic resection, ~ 30% will have IPMNs that 
have an associated invasiveadenocarcinoma.46,57 This invasive adenocarcinoma can be 
either colloid carcinoma (mucinous non-cystic adenocarcinoma) or a conventional tubular-
type adenocarcinoma.58 As noted earlier, the colloid carcinomas almost always arise in 
association with an intestinal-type intraductal papillary mucinous neoplasm.59,60
Patients with an invasive carcinoma arising in association with an intraductal papillary 
mucinous neoplasm have a better prognosis than do patients with a conventional ductal 
adenocarcinoma not arising in association with an IPMN, but some of this improved 
prognosis is lost when one controls for stage.46,61
Molecular Genetics of IPMNs
The genetic alterations in intraductal papillary mucinous neoplasms have been characterized 
using whole exome sequencing. IPMNs harbor fewer genetic alterations than do invasive 
ductal adenocarcinomas. Some of the genes targeted in intraductal papillary mucinous 
neoplasms are also targeted in ductal adenocarcinomas (such as KRAS, p16/CDKN2A, TP53 
and SMAD4), while others are more specific for the IPMN pathway (such as GNAS and 
RNF43).47,62 Somatic mutations in KRAS are common and early events in the development 
of intraductal papillary mucinous neoplasms (up to 80% cases)63,64 These mutations can be 
detected in fluid aspirated from the cysts.47 TP53 gene mutations have also been reported in 
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intraductal papillary mucinous neoplasms, and the prevalence of these mutations increases 
with the grade of dysplasia, whereas SMAD4 mutations are uncommon in IPMNs unless 
there is an associated invasive adenocarcinoma.65–70
Whole-exome sequencing of intraductal papillary mucinous neoplasms also revealed 
mutations in two genes that are not commonly targeted in usual ductal adenocarcinomas. 
The GNAS oncogene located on chromosome 20q13.3 encodes for G protein stimulating α 
subunit and is mutated at single hotspot codon201 in 65% of IPMNs.45,47,64 Mutations in 
the GNAS gene result in the constitutive activation of Gsα and its effector adenylate cyclase, 
leading to autonomous synthesis of cyclic AMP (cAMP) and uncontrolled growth 
signaling.71 GNAS mutations are most common in intestinal type IPMNs (100%) followed 
by pancreatobiliary (70%) and gastric types (50 %). Interestingly, patients with McCune 
Albright syndrome which arises from post-zygotic oncogenic mutations in GNAS have been 
reported to have pancreatic cysts.72 Of note, the GNAS mutations present in IPMNs can be 
detected in cyst fluid aspirates and even in duodenal fluids collected at the time of 
endoscopy. For example, Kanda et al. reported that GNAS mutations are detectable in two-
thirds of pancreatic secretions collected from duodenal contents of patients with an IPMN. 
Remarkably, GNAS mutations were detected in some patients who did not have an IPMN 
detectable by imaging at the time they were studied, but who later developed an IPMN.45,73 
The combination of testing for KRAS and GNAS mutations may prove a very sensitive 
approach to analyzing cyst fluids and to the early detection of pancreatic neoplasms, as 95% 
of IPMNs have mutations in one of these two oncogenes.
The RNF43 gene located on chromosome 17q23.2 encodes for a protein with intrinsic E3 
ubiquitin ligase activity, and RNF43 is commonly (up to 75% of studied cases) inactivated 
in IPMNs.62 The protein product of the RNF43 gene is involved in regulating Wnt signaling, 
and may be therapeutically targetable.74–76 Jiang et al have shown that inactivating 
mutations in RNF43 confer Wnt pathway dependency, and that cells with an RNF43 gene 
mutation are particularly sensitive to the porcupine inhibitor LGK974.75
Thus, the sequencing of IPMNs has identified genetic changes that may help classify a cyst 
as an IPMN, changes that may be useful for early detection and genetic changes that may be 
therapeutically targetable.
Mucinous cystic neoplasm
Mucinous cystic neoplasms (MCNs) of pancreas are distinctive mucin-producing neoplasms 
that arise almost exclusively in the body and tail of pancreas.2 Most cases occur in young or 
middle aged females. In contrast to IPMNs, the cysts of MCN do not communicate with the 
larger pancreatic ducts. The cysts are most frequently multi-loculated and distended with 
tenacious mucin. Grossly, the inner surfaces of the cyst walls may be smooth, they may have 
papillary excrescences or they may have isolated intracystic solid nodules. Microscopic 
examination show two characteristic components: 1) cysts lined with columnar mucinous 
type epithelium arranged in a flat or papillary architecture, and 2) distinctive ovarian-type 
stroma, the cells of which may express estrogen and progesterone receptors.2 As is true for 
IPMNs, the cytological atypia of the lining epithelium is graded as low, intermediate and 
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high grade. MCNs are precursors to invasive cancer, and up to one-third of MCNs have an 
associated invasive carcinoma.
Molecular Genetics of MCNs
The exomes of a series of well-characterized MCNs have been sequenced, and MCNs 
harbor fewer mutations than do ductal adenocarcinomas.62 The KRAS, p16/CDKN2A, TP53, 
RNF43 and SMAD4 genes have all been reported to be targeted in MCNs. Somatic KRAS 
mutations are the most common and their prevalence increases as histologic grade 
increases.77,78 Majority (80%) of MCNs associated with invasive tumor or high grade 
dysplasia has KRAS mutations as compared to only 30% of MCNs with low-grade 
dysplasia.78 SMAD4, TP53 and p16/CDKN2A genes all appear to be targeted in higher-
grade lesions.39,70,79 Approximately 40% of MCNs harbor somatic mutations in tumor 
suppressor RNF43, which is also targeted in IPMNs, suggesting the role of this gene in the 
development of mucin-producing neoplasms of pancreas.62 In contrast to IPMNs, GNAS 
does not appear to be mutated in MCNs.47
Solid-pseudopapillary neoplasm
Solid-pseudopapillary neoplasms (SPNs) are rare solid neoplasms of the pancreas that 
typically undergo cystic degeneration. The vast majority arise in young women.2 Although 
these lesions often carry a favorable prognosis, they are fully malignant neoplasms, and 
local invasion or even metastases occur in 10–15% of patients.80,81 There is no definite 
predilection for anatomical location within the pancreas. Grossly SPNs are well 
circumscribed with solid (cellular) and cystic (degenerative) areas. Microscopically, SPNs 
are composed of bland appearing cells with clear cell features and uniform nuclear 
morphology arranged in sheets and a pseudopapillary configuration. Characteristic pseudo-
papillae are acquired due to degenerative changes and loss of cellular cohesion, which 
leaves a thin layer of neoplastic cells lining delicate vessels. Degenerative features include 
foam cells, hyalinization, cholesterol clefts, microcystic change and hemorrhage. Hyaline 
globules are frequently present.(Fig 1B) The neoplastic cells characteristically invade in the 
adjacent pancreatic parenchyma by insinuating themselves between non-neoplastic cells.82 
SPNs may have considerable morphologic overlap with pancreatic neuroendocrine tumors. 
An immunolabeling panel that includes CD10 and β-catenin (nuclear expression, Fig 1C) 
may aid in making diagnosis of SPN.82 Characteristic dot like paranuclear (Golgi zone) 
immunolabeling is also reported for CD99.83 While the presence of focal degenerative 
atypia is not prognostically significant, the presence of a dedifferentiated component 
portends a significantly worse prognosis.80,84
Molecular Genetics of SPNs
The exomes of SPNs have been sequenced and SPNs have an average of only three non-
synonymous mutations per tumor, the lowest number of any adult solid tumor sequenced to 
date.62 The genes targeted in SPNs are different from those targeted in other tumors of the 
pancreas. Alterations in TP53, KRAS, p16/CDKN2A, and SMAD4 are not seen. Instead, the 
Wnt/β-catenin signaling pathway is activated in almost all SPNs.85 Almost all SPNs (95%) 
have somatic activating mutations in the β-catenin gene (exon 3 of CTNNB1) leading to 
Rishi et al. Page 8
Semin Oncol. Author manuscript; available in PMC 2016 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
abnormal nuclear localization of the β-catenin protein.86,87 This aberrant nuclear localization 
of β-catenin can be exploited diagnostically, as nuclear labeling for the β-catenin protein can 
be used to distinguish SPNs from other pancreatic neoplasms. Loss of β-catenin is associated 
with alterations in the pattern of E-cadherin expression. Immunolabeling with antibodies to 
the extracellular domain of E-cadherin show a loss of membrane staining, while an aberrant 
nuclear pattern of labeling isseen with antibodies to the intracellular domain.88,89 Loss of the 
adhesion molecule E-cadherin may also explain the dyscohesive nature of the neoplastic 
cells in SPNs.
Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (PanNETs) are a morphologically and genetically distinct 
category of pancreatic neoplasms with neuroendocrine differentiation, accounting for ~1% 
of diagnosed pancreatic neoplasms.2,90,91 Although less aggressive than ductal 
adenocarcinomas, neuroendocrine tumors (≥0.5cm) are malignant neoplasms with a five-
year survival of only 65%. These neoplasms can produce hormones that can cause 
significant clinical symptoms (“functional tumors”) and can arise in patients with a genetic 
syndrome such as the multiple neuroendocrine neoplasia type 1 (MEN-1) syndrome. The 
clinical presentation is variable and is based on the functional status of the tumor. There is 
no specific anatomical predilection within the pancreas. Sporadic neoplasms are often 
solitary in contrast to the multi-focality of PanNETs associated with multiple endocrine 
neoplasia (MEN-1) syndrome.
These well-circumscribed neoplasms may have a fibrous capsule and are usually tan-yellow 
and solid. Some examples are hemorrhagic, while others may be cystic. Necrosis and 
degeneration are more common in larger tumors. The histological differentiation ranges 
from well to poorly differentiated, and grading is based entirely on the proliferation rate. In 
the World Health Organization (WHO)-2010 classification, well-differentiated tumors are 
classified into grade 1 (mitosis < 2/10 high power field or HPF; Ki-67 proliferation < 3%) 
and grade 2 (mitosis 2–20/10 HPF; Ki-67 proliferation 3–20%).92 Poorly differentiated 
tumors are classified as grade 3 with mitosis and Ki-67 proliferation index of greater than 
20/HPF and 20% respectively. Grade 3 neuroendocrine tumors are designated carcinomas. 
When assessing the proliferation rate of neuroendocrine tumors, the inclusion of both the 
mitotic rate and Ki-67 labeling index can help refine prognostication.93
Molecular genetics of PanNETs
The genes targeted in neuroendocrine tumors differ significantly from those targeted in 
ductal adenocarcinomas. Whole exome sequencing shows an average of 16 nonsynonymous 
mutations per tumor, far fewer than in ductal adenocarcinoma.94 The genes commonly 
targeted in neuroendocrine tumors include MEN1, DAXX and ATRX, and genes coding for 
members of the mammalian target of rapamycin (mTOR) pathway.94–97 DAXX (death-
domain-associated protein) and ATRX (α thalassemia/mental retardation syndrome X-
linked) are chromatin remodeling genes, and one of these genes is somatically mutated in 
45% of sporadic PanNETs. These genes encode nuclear proteins that mutually interact and 
function in chromatin remodeling at telomeric and peri-centromeric regions. 
Immunolabeling for the DAXX and ATRX proteins correlates with gene status.(Fig 1D) 
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Mutations in these genes are associated with the alternative lengthening of telomeres (ALT) 
phenotype, a telomerase independent mechanism for telomere maintenance.98 Mutations in 
MEN1, DAXX and ATRX are associated with better prognosis than wild-type tumors. 
Somatic mutations in DAXX and ATRX are acquired late in PanNET oncogenesis as shown 
by their absence in microadenomas.99 Mutations in mTOR (mammalian target of 
rapamycin) pathway including PIK3CA, PTEN and TSC2 are present in 14% of PanNETs 
and may be candidate for treatment with mTOR pathway inhibitors.94,100 Although the VHL 
gene is not commonly altered by small somatic mutations in sporadic tumors, the VHL/HIF 
pathway is also important in PanNET pathogenesis.101 Pancreatic neuroendocrine 
microadenomas are present in >70% of patients with von Hippel Lindau syndrome. Sporadic 
PanNETs rarely harbor somatic VHL gene mutation, but promoter hypermethylation and 
deletion of VHL occur in up to 25% sporadic PanNETs and are associated with adverse 
prognosis.102
Acinar Cell Carcinoma
Acinar cell carcinomas (ACCs) are rare pancreatic neoplasms. They have poor prognosis 
and considerable morphologic overlap with pancreatoblastoma – both neoplasms have 
acinar differentiation, though pancreatoblastoma also displays other types of differentiation 
(see below). The mean survival of patients with an acinar cell carcinoma is 18–24 months 
and the 3 year survival rate is only 25%.103,104There is no anatomical predilection within the 
pancreas, and frequent presentation is in the form of a large solitary, solid and well-
circumscribed mass lesion. Microscopically, they are cellular neoplasms with acinar cell 
differentiation, based on morphology and immunohistochemical staining. The cyanophilic 
acinar appearing cells consist of granular cytoplasm and centrally located nucleus with 
prominent nucleolus, which are arranged in sheets and trabecular pattern.2
Molecular genetics of ACCs
Recent whole exome sequencing of acinar cell carcinomas revealed a mean of 119 non-
synonymous mutations, which is higher than the average number of mutations in ductal 
adenocarcinomas and other primary pancreatic neoplasms.105 These carcinomas display 
striking genomic instability, and multiple genetic aberrations are often present, including 
large chromosomal gains and losses and microsatellite instability. At the gene level, genes 
coding for members of the APC–β-catenin pathway are targeted in 20–25% of acinar cell 
carcinomas,106 while KRAS and TP53 are only rarely targeted. Of particular note, potentially 
therapeutically targetable mutations have been identified in some acinar cell carcinomas, 
including mutations in genes coding for members of the Fanconi anemia pathway, which 
would potentially be targetable with poly (ADP-ribose) polymerase (PARP) inhibitors. 
Other potentially targetable genetic alterations in acinar cell carcinomas include mutations in 
BRAF and JAK1.105,107–109
Pancreatoblastoma
Pancreatoblastomas (PBs) are very rare pancreatic neoplasms that have a bimodal age 
distribution with one peak in pediatric patients and the other later in adulthood.110 The 
prognosis is strongly influenced by the completeness of surgical resection.111 There is no 
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location preference within the pancreas.112 The microscopic appearance of 
pancreatoblastomas is diverse, but at a minimum pancreatoblastomas contains cells with 
acinar differentiation and squamoid nests.2 Other common directions of differentiation 
include neuroendocrine and primitive blastemal histomorphology. The neoplastic cells are 
arranged in sheets,tubules, nests and acinar patterns. Presence of squamoid nests 
differentiates pancreatoblastomas from acinar cell carcinomas.
Molecular genetics of PBs
The genetic aberrations in pancreatoblastoma are not well-characterized because these 
neoplasms are so rare.105 At the genetic level, pancreatoblastomas bear closer resemblance 
to the infantile embryonal tumors as suggested by their reported occurrence with Beckwith-
Wiedemann syndrome and chromosome 11p loss.113 Most commonly the somatic 
inactivating mutations involve APC / β-catenin pathway. Allelic loss on 11p15.5 is present 
in 86% cases.113 Infrequently there is diffuse loss of Smad4 protein expression in 22% 
cases. Somatic mutations in KRAS or TP53 are not reported in pancreatoblastomas.113
Conclusion
Detailed molecular and genetic analyses of pancreatic neoplasms show that each tumor type 
has its own unique set of genetic aberrations (Table 1), which are important for molecular 
sub-classification, screening, prognostication and prospective targeted treatment. Some of 
the mutations occur in very early precursor lesions, suggesting that they may be useful 
targets in early detection tests, while others are late events, suggesting they may be more 
suitable for targeted therapies. We are confident that an improved understanding of the 
important molecular and genetic changes of pancreatic neoplasms will ultimately help 
improve the diagnosis and management of patients with these tumors.
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Figure 1. 
A: DPC4 immunohistochemistry with complete loss of immunolabeling in the pancreatic 
ductal adenocarcinoma. Note the intact staining in non-neoplastic islet cells. (×100)
B: Solid-pseudopapillary neoplasm of the pancreas showing hyaline globules and bland 
monomorphic neoplastic cells with nuclear grooves, pale chromatin and inconspicuous 
nucleoli. (Hematoxylin &Eosin × 200)
C: β-Catenin immunolabeling of solid-pseudopapillary neoplasm with strong nuclear and 
cytoplasmic staining. (×200)
D: Pancreatic neuroendocrine tumor with loss of nuclear immunolabeling for the protein 
product of ATRX (α thalassemia/mental retardation syndrome X-linked) chromatin 
remodeling gene. Note the intact nuclear staining in non-neoplastic endothelial cells. (×400)
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Table 1
Frequently targeted genes in pancreatic neoplasms
Pancreatic neoplasm Targeted gene Alteration prevalence Altered gene function
PDCA KRAS 90% Cell cycle activation (MAPK and PIK3CA 
pathway)
P16/CDKN2A 95% CDK4 and CDK6 inhibition
TP53 75% Cellular stress response
SMAD4 55% Loss of TGF-β induced tumor suppression
IPMN KRAS 80% Cell cycle activation (MAPK and PIK3CA 
pathway)
P16/CDKN2A Present only in high grade dysplasia 
and carcinoma
CDK4 and CDK6 inhibition
TP53 Cellular stress response
SMAD4 Loss of TGF-β induced tumor suppression
GNAS 60–65%
IPMN variants
Intestinal – 100%
Pancreatobiliary – 71%
Gastric type – 51%
Uncontrolled growth signaling
RNF43 75% Wnt signaling regulation
MCN KRAS 30% – 80%
Progressive increase with dysplasia 
grade
Cell cycle activation
RNF43 40% Wnt signaling regulation
P16/CDK2NA, TP53, SMAD4 Only in high grade tumors
SPN CTNNB1 95% Wnt/β-catenin signaling pathway 
activation
PanNET MEN1 45%
DAXX and ATRX 45% Chromatin remodeling
PIK3CA, PTEN and TSC2 14% mTOR pathway
VHL 25% HIF-1 α pathway
ACC APC–β-catenin 25% Cell signaling and adhesion
KRAS Rare Cell cycle activation
TP53 Rare Cellular stress response
Fanconi anemia pathway genes 45% DNA repair mechanism
CTNNB1 5% Cell signaling and adhesion
PB APC–β-catenin 86% Cell signaling and adhesion
CTNNB1 55% Cell signaling and adhesion
PDCA: pancreatic ductal adenocarcinoma, IPMN: intraductal papillary and mucinous neoplasm, MCN: mucinous cystic neoplasm, SPN: solid and 
pseudopapillary neoplasm, PanNET: pancreatic neuroendocrine tumor, ACC: acinar cell carcinoma, PB: pancreatoblastoma
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